
Luigi Principe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3353493/publications.pdf Version: 2024-02-01



LUICI PRINCIPE

#	Article	IF	CITATIONS
1	The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics, 2021, 10, 1012.	3.7	73
2	Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. Journal of Global Antimicrobial Resistance, 2021, 25, 268-281.	2.2	62
3	Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics, 2020, 9, 500.	3.7	38
4	Characterization of resistance mechanisms and genetic relatedness of carbapenem-resistant Acinetobacter baumannii isolated from blood, Italy. Diagnostic Microbiology and Infectious Disease, 2013, 75, 180-186.	1.8	30
5	First report of NDM-1-producing Klebsiella pneumoniae imported from Africa to Italy: Evidence of the need for continuous surveillance. Journal of Global Antimicrobial Resistance, 2017, 8, 23-27.	2.2	20
6	Zinc Chelators as Carbapenem Adjuvants for Metallo-β-Lactamase-Producing Bacteria: <i>In Vitro</i> and <i>In Vivo</i> Evaluation. Microbial Drug Resistance, 2020, 26, 1133-1143.	2.0	17
7	Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically III COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers. Microorganisms, 2022, 10, 362.	3.6	14
8	Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales. International Journal of Antimicrobial Agents, 2021, 58, 106362.	2.5	13
9	Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. Antibiotics, 2021, 10, 1341.	3.7	13
10	Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/I²-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians. Pharmaceuticals, 2022, 15, 463.	3.8	13
11	Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey. Anaerobe, 2022, 75, 102583.	2.1	13
12	Aspirin and Infection: A Narrative Review. Biomedicines, 2022, 10, 263.	3.2	9
13	Antimicrobial Susceptibility, Virulence, and Genomic Features of a Hypervirulent Serotype K2, ST65 Klebsiella pneumoniae Causing Meningitis in Italy. Antibiotics, 2022, 11, 261.	3.7	8
14	Whole-Genome Sequencing Investigation of a Large Nosocomial Outbreak Caused by ST131 H30Rx KPC-Producing Escherichia coli in Italy. Antibiotics, 2021, 10, 718.	3.7	7
15	<i>In vitro</i> activity of ceftazidime/avibactam against clinical isolates of ESBL-producing <i>Enterobacteriaceae</i> in Italy. Journal of Chemotherapy, 2019, 31, 195-201.	1.5	4
16	Emergence of Haemophilus parainfluenzae resistant to third-generation cephalosporins in Italy: potential role of PBP3 and PBP5 substitutions in high-level resistance. International Journal of Antimicrobial Agents, 2020, 56, 106159.	2.5	3
17	In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples. Antibiotics, 2021, 10, 1309.	3.7	3
18	Novel vanA-carrying plasmid in a clinical isolate of Enterococcus avium. International Journal of Antimicrobial Agents, 2019, 53, 876-877.	2.5	2

#	Article	IF	CITATIONS
19	New Antimicrobial Options in the Clinical Practice of Infections Caused by Difficult-to-Treat Pathogens: A Global Opportunity for Public Health. Antibiotics, 2022, 11, 740.	3.7	0